Reports
Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size, Share, Analysis, Growth, Forecast: By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis; By Diagnosis Method; By Treatment Method; By Treatment Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Outlook
The global focal segmental glomerulosclerosis (FSGS) treatment market attained a value of USD 21.8 billion in 2022. The market is expected to grow further at a CAGR of 8.25% during the forecast period of 2023-2031 to attain a value of 44.5 billion by 2031, driven by the rising prevalence of the diabetes and other kidney disorders.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Introduction
Focal segmental glomerulosclerosis is a serious kidney disorder which can lead to kidney failure. In this disease, a scar tissue gets developed in the small parts of the kidneys, known as glomeruli, that filter waste from the blood. It can be caused due to various factors including diabetes, obesity, sickle cell disease, infection, drug toxicity, inherited abnormal genes, or any other kidney ailments.
The condition can be of different types and the treatment pathway significantly depends on the type of the disease. The different types of focal segmental glomerulosclerosis (FSGS) include the following:
Primary FSGS- This type of FSGA happens when the exact cause remains unknown, the source remains unknown.
Secondary FSGS- The secondary type might be caused due to consumption of some drug or due to another disease. The causes can include various factors like drug toxicity, diabetes, infection, sickle cell disease, other kidney ailments. Targeting these underlying causes can lead to the slow progression of kidney damage and might heal the functioning of the kidney over time.
There is one more type, known as the genetic FSGS, which is the rare form of the disease and also referred to as familial FSGS. This type of FSGS is usually caused due to genetic factors. However, it can happen to people whose parents are not affected but might be carrying a copy of an altered gene, which can unknowingly be passed on to the next generations.
Common symptoms of focal segmental glomerulosclerosis (FSGS) include the following:
- Swelling in Body Parts
- Low Levels of Protein in the Blood
- High Blood Sugar
- Weight Gain Due to Additional Fluids
- High Cholesterol
- Proteinuria (High Level of Protein in the Urine)
In some cases, FSGS can also cause nephrotic syndrome where the above mentioned symptoms, along with some additional symptoms, can show up altogether and can severely affect the kidneys. If the condition advances further, the patient might experience symptoms like fatigue, nausea, shortness of breath, poor appetite, headache, and itchy skin.
Diagnostic Methods in The Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
FSGS can be diagnosed with a blood test, urine test, and a kidney biopsy.
Urine Test: A urine test will help find protein and blood in your urine.
Blood Test: A blood test will help find levels of protein, cholesterol, and wastes in your blood.
Glomerular Filtration Rate (GFR): A blood test will be done to know how well your kidneys are filtering the wastes from your body.
Kidney Biopsy: In this test, a tiny piece of your kidney is removed with a special needle and looked at under a microscope.
Genetic Testing: A genetic test may be done to see if you were born with genes that caused your kidney disease. This information may help your doctor decide what type of treatment is best for you.
Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Segmentations
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The focal segmental glomerulosclerosis (FSGS) treatment market can be categorised into disease type, diagnostic method, treatment method, treatment channel, and region.
Market Breakup by Disease Type
- Primary Focal Segmental Glomerulosclerosis
- Secondary Focal Segmental Glomerulosclerosis
Market Breakup by Diagnosis Method
- Kidney Function Testing
- Kidney Imaging
- Kidney Biopsy
Market Breakup by Treatment Method
- Medication
- Dialysis
- Kidney Transplant
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Focal Segmental Glomerulosclerosis (FSGS) Treatment Market- Epidemiology
The condition is more prevalent in people of all ages but affects males more than females. In terms of race, the disease is most likely to happen to African Americans.
Focal Segmental Glomerulosclerosis (FSGS) Treatment Market- Therapeutic Landscape
The treatment pathway can be of the following types and depends on the kinds of symptoms:
Medications- These are used to control the symptoms in order to limit the progression of FSGS and control it as much as possible. The most common medicines used in the treatment of FSGS include angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB) medication, cyclosporine, and prednisone, among others.
Dialysis- There are two types of dialysis that help in the normal functioning of the kidney, haemodialysis and peritoneal dialysis. Dialysis helps your body remove wastes and toxins from the body when the kidney becomes unable to.
Kidney Transplant- Transplant is the preferred method of treatment when the kidney of a person is barely working or stops working completely. A healthy kidney, either from a living person or a deceased person, is transplanted in the patient to enable the functioning of the kidney.
Key Players in the Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
- Variant Pharmaceuticals, Inc.
- Travere Therapeutics, Inc.
- Sanofi S.A.
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Aurinia Pharmaceuticals Inc.
- Medtronic Plc.
- B. Braun Melsungen AG
- Bristol-Myers Squibb Co.
- Reata Pharmaceuticals Inc
- Kyowa Hakko Kirin Co., Ltd.
- Astellas Pharma Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2023 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Diagnosis Method |
|
| Breakup by Treatment Method |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Focal Segmental Glomerulosclerosis (FSGS) Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
8.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Overview
8.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Forecast Value (2023-2031)
8.3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market by Disease Type
8.3.1 Market Overview
8.3.1.1 Primary Focal Segmental Glomerulosclerosis
8.3.1.2 Secondary Focal Segmental Glomerulosclerosis
8.4 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market by Diagnosis Method
8.4.1 Market Overview
8.4.1.1 Kidney Function Testing
8.4.1.2 Kidney Imaging
8.4.1.3 Kidney Biopsy
8.5 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market by Treatment Method
8.5.1 Market Overview
8.5.1.1 Medication
8.5.1.2 Dialysis
8.5.1.3 Kidney Transplant
8.6 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market by Treatment Channel
8.6.1 Public
8.6.2 Private
8.7 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market by Region
8.7.1 Market Overview
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives, and Trends
9.7 Value Chain Analysis
10 Supplier Landscape
10.1 Beckman Coulter Inc. (Danaher Corporation)
10.1.1 Company Overview
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.1.5 Certifications
10.2 Complexa Inc.
10.2.1 Company Overview
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.2.5 Certifications
10.3 Variant Pharmaceuticals, Inc.
10.3.1 Company Overview
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.3.5 Certifications
10.4 Travere Therapeutics, Inc.
10.4.1 Company Overview
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.4.5 Certifications
10.5 Sanofi S.A.
10.5.1 Company Overview
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.5.5 Certifications
10.6 Pfizer Inc.
10.6.1 Company Overview
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.6.5 Certifications
10.7 GlaxoSmithKline Plc.
10.7.1 Company Overview
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.7.5 Certifications
10.8 Aurinia Pharmaceuticals Inc.
10.8.1 Company Overview
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.8.5 Certifications
10.9 Medtronic Plc.
10.9.1 Company Overview
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.9.5 Certifications
10.10 B. Braun Melsungen AG
10.10.1 Company Overview
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.10.5 Certifications
10.11 Bristol-Myers Squibb Co
10.11.1 Company Overview
10.11.2 Product Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Mergers and Acquisitions
10.11.5 Certifications
10.12 Reata Pharmaceuticals Inc
10.12.1 Company Overview
10.12.2 Product Portfolio
10.12.3 Demographic Reach and Achievements
10.12.4 Mergers and Acquisitions
10.12.5 Certifications
10.13 Kyowa Hakko Kirin Co., Ltd.
10.13.1 Company Overview
10.13.2 Product Portfolio
10.13.3 Demographic Reach and Achievements
10.13.4 Mergers and Acquisitions
10.13.5 Certifications
10.14 Astellas Pharma Inc.
10.14.1 Company Overview
10.14.2 Product Portfolio
10.14.3 Demographic Reach and Achievements
10.14.4 Mergers and Acquisitions
10.14.5 Certifications
11 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market- Drug Distribution Model (Additional Insight)
11.1 Overview
11.2 Potential Distributors
11.3 Key Parameters for Distribution Partner Assessment
12 Payment Methods (Additional Insight)
12.1 Government Funded
12.2 Private Insurance
12.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The focal segmental glomerulosclerosis (FSGS) treatment market attained a value of USD 21.8 billion in 2022.
The market is projected to grow at a CAGR of 8.25% during the forecast period of 2023-2031.
The market is estimated to witness healthy growth during the forecast period of 2023-2031 to reach a value of USD 44.5 billion by 2031.
The growth of the market is driven by factors like rising prevalence of kidney disorders.
The key trends in the market include the rising support of the government in kidney treatments.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The disease types include primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis.
The diagnostic methods include kidney function testing, kidney imaging, and kidney biopsy.
Treatment methods can be classified into medication, dialysis, and kidney transplant.
Treatment channels can be categorised into public and private channels.
The major players in the market are Variant Pharmaceuticals, Inc., Inc., Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Aurinia Pharmaceuticals Inc., Medtronic Plc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Reata Pharmaceuticals Inc., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., and Travere Therapeutics.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER